Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL893723 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL3504659 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL1065178 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL21454626 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL321552 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL336249 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL17512849 | 1.00 | HSD17B10 (0.56) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL21320722 | 0.97 | HSD17B10 (0.54) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 | |
| SCHEMBL1661688 | 0.97 | — | — | |
| SCHEMBL661575 | 0.97 | HSD17B10 (0.58) | HSD17B10GAAALDH1A1SLC6A9CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1924 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4211146-B1 | SYNTHETIC CYCLIC PEPTIDE MIMETICS | UNIV BAR ILAN (IL) | 2026-05-20 | — | — | EP | claimed |
| EP-3986465-B1 | SITE-SPECIFIC, KINETICALLY INERT CONJUGATION OF LABELS AND/OR CARRIERS TO TARGET MOLECULES SUCH AS HIS-TAGGED PROTEINS VIA METAL COMPLEX REAGENTS | MAX PLANCK GESELLSCHAFT (DE) | 2026-05-13 | — | — | EP | claimed |
| US-12616760-B2 | Synthetic cyclic peptide mimetics | BAR ILAN UNIVERSITY (IL) | 2026-05-05 | — | — | US | claimed |
| US-20260108637-A1 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | UNIV JOHNS HOPKINS (US) | 2026-04-23 | — | — | US | claimed |
| EP-4727561-A1 | TREATMENT OF SOLID TUMORS WITH A REGIMEN OF TARGETED RADIONUCLIDE THERAPY AND GENETICALLY ENGINEERED IMMUNE CELL THERAPIES | Wisconsin Alumni Research Foundation (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4719494-A2 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | The Johns Hopkins University (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4719498-A1 | RADIOLIGANDS FOR TARGETING CELL SURFACE RECEPTORS AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| EP-4719486-A1 | CONJUGATES AND USES THEREOF | Full-Life Technologies UK Limited (GB) | 2026-04-08 | — | — | EP | claimed |
| EP-4713029-A1 | MODIFIED CELL, PHARMACEUTICAL COMPOSITION AND METHOD OF PREPARING A MODIFIED CELL | Max-Planck-Gesellschaft zur Förderung der Wissenschaften E.V. (DE) | 2026-03-25 | — | — | EP | claimed |
| US-12576168-B2 | Peptide PET/SPECT probes specific to oncoproteins in tumor extracellular matrix | CASE WESTERN RESERVE UNIVERSITY (US) | 2026-03-17 | — | — | US | claimed |
| US-20030060382-A1 | Solution composition for removing a remaining photoresist resin | HYNIX SEMICONDUCTOR INC. (KR) | 2003-03-27 | — | — | US | claimed |
| WO-2002067859-A3 | ASCORBIC ACID ANALOGS FOR METALLORADIOPHARMACEUTICALS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-11-28 | — | — | WO | claimed |
| US-20020122769-A1 | Ascorbic acid analogs for metalloradiopharmaceuticals | LANTHEUS MEDICAL IMAGING, INC. | 2002-09-05 | — | — | US | claimed |
| EP-0766968-B1 | Diagnostic imaging agent | NIHON MEDIPHYSICS CO LTD (JP) | 2001-01-17 | — | — | EP | claimed |
| US-6030840-A | CONTACTING CHELATED LANTHANIDE METAL IONS BOUND TO MARKER WITH BUFFERED SOLUTION OF DETERGENT, ENHANCER REAGENT AND POLYANION; IONS DISSOCIATE FROM MARKER AND REASSOCIATE WITH ENHANCER; THEN DETERMINING AMOUNT OF IONS LIBERATED | NEN LIFE SCIENCES, INC. (US) | 2000-02-29 | — | — | US | claimed |
| WO-1999066333-A1 | NEUTRAL ENHANCEMENT OF LANTHANIDES FOR TIME RESOLVED FLUORESCENCE | NEN LIFE SCIENCE PRODUCTS, INC. (US) | 1999-12-23 | — | — | WO | claimed |
| US-5863518-A | BIFUNCTIONAL POLYAMINOPOLYCARBOXYLIC ACID LIGAND IS BONDED TO AMINO OLIGOSACCHARIDE COMPOSED OF 3 TO 6 MONOSACCHARIDE AND HAVING A REDUCING END OF SUGAR CHAIN, OR AN ALDEHYDE GROUP OF SUGAR CHAIN, AND COORDINATED TO METAL ION | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1999-01-26 | — | — | US | claimed |
| EP-0766968-A1 | Diagnostic imaging agent | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1997-04-09 | — | — | EP | claimed |
| EP-0709100-A1 | Contrast agent, containing several detection groups per molecule | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1996-05-01 | — | — | EP | claimed |
| EP-0707857-A1 | Chitosan oligomer derivatives, labelled with Gd-DTPA, for use as magnetic resonance contrast agents | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1996-04-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616760-B2 | Synthetic cyclic peptide mimetics | TPX2, IAPP, HAX1 | HSD17B10 4795/4885GAA 1158/4885ALDH1A1 4698/4885 |
| US-20020122769-A1 | Ascorbic acid analogs for metalloradiopharmaceuticals | SLC40A1, TTPA, SLC39A14 | HSD17B10 3734/4885GAA 325/4885ALDH1A1 222/4885 |
| US-12576168-B2 | Peptide PET/SPECT probes specific to oncoproteins in tumor extracellular matrix | FN1, INHA, EDNRB | HSD17B10 4785/4885GAA 2461/4885ALDH1A1 4553/4885 |
| US-20260108637-A1 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | MUSK, TNNC1, TNNI3 | HSD17B10 4069/4885GAA 1395/4885ALDH1A1 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.